Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268373 | PMC |
http://dx.doi.org/10.2147/PPA.S485396 | DOI Listing |
Neuropsychiatr Dis Treat
January 2025
Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA.
Peripartum depression (PPD) affects approximately one in every eight birthing individuals. Despite a high prevalence, PPD is underdiagnosed and undertreated. Several PPD treatment options exist including psychotherapies, conventional serotonergic-based antidepressants and alternative and integrative medicine approaches.
View Article and Find Full Text PDFFront Oral Health
January 2025
Hospital of Stomatology, Sun Yat-sen University, Guangzhou, China.
Objectives: This study aims to examine kindergarten teachers' satisfaction and their perceived impact of an oral health education (OHE) training program.
Methods: This study followed the steps outlined in the Program Evaluation Standards in Public Health recommended by the Centers for Disease Control and Prevention. All kindergarten teachers in Hong Kong were invited to attend the OHE training.
Digit Health
January 2025
Leeder Centre for Health Policy, Economics and Data, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Objective: Digital health technologies offer a more equitable way of providing access to health education. This study engaged consumers and clinicians from two Australian regions with a high burden of oral disease to develop a digital oral health resource called "TOOTH" tailored for adults.
Methods: A total of three focus groups (one clinician and two consumers) were conducted to identify themes that were used to draft text message content.
Value Health
January 2025
Department of Cardiology and State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Objective: Our objective was to develop and assess the psychometric properties of relevant bolt-on items for the EQ-5D-5L in patients with rare diseases (RDs).
Methods: Nineteen new EQ-5D-5L bolt-ons were developed based on literature review, expert input and qualitative interviews and focus groups with patients, caregivers and representatives of patient associations. A nationwide, cross-sectional, web-based survey in China included patients or caregivers of patients with 31 RDs in China (n=9,190).
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!